{"13":["Ягудина Р. ФАРМАКОЭКОНОМИКА. Том 4, №4, 2011,с. 3-7"," "],"24":["Papp K. et al. Lancet. 2008:371:1675-84 "],"31":["Инструкция по медицинскому примененияю препарата Стерала® (устекинумаб) ЛП-001104, ЛСР-006465/09 Электронный ресурс 25.08.2017 http://grls.rosminzdrav.ru/ \u0003Инструкция по медицинскому примерения препарата Секукинумаб ЛП-0037870, ЛП-003715. Электронный ресурс 25.08.2017 http://grls.rosminzdrav.ru/  \u0003Thaci D J AM Dermatol. 2015 Sep;73(3);400-9. doi: 10.1016/j.laad.2015.05.013. Epub 2015 Jun 17 Thaci D J AM Dermatol. 2015 Sep;73(3);400-9"],"39":["1. Kavanaugh A, et al. Arthritis Care Res. 2015;67(12):1739–49","2. Kavanaugh A et al. Ann Rheum Dis. 2016 Nov;75(11):1984-1988. "],"46":["Kavanaugh A et al. Ann Rheum Dis. 2016 Nov;75(11):1984-1988.."],"51":["Wendler J. et al, Ustekinumab for the treatment of psoriatic arthritis – Results of the first Interim analysis of the non-interventional study SUSTAIN, 44th of DGRh, 2016, Frankfurt, SP.36","Wendler J. et al.. THU0280, Annals of the Rheumatic Diseases 2018;77:358. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6364",""],"52":["Wendler J. et al, Ustekinumab for the treatment of psoriatic arthritis – Results of the first Interim analysis of the non-interventional study SUSTAIN, 44th of DGRh, 2016, Frankfurt, SP.36","Wendler J. et al.. THU0280, Annals of the Rheumatic Diseases 2018;77:358. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6364",""],"60":["Gisondi et Al. Br J Dermond. 2013 May: 168(5): 1124-7"],"64":["Kavanaugh A, et al. Arthritis Care Res. 2015;67(12):1739–49","Kavanaugh A et al. Ann Rheum Dis. 2016 Nov;75(11):1984-1988. "],"67":["Araujo et al. Semin Arthritis Rheumatism 2018; Epub 13JUN doi: 10.1016/j.semarthrit.","2018.05.011."],"71":["Rich P et al. Ustekinumab improves nail disease in patients with","moderate-to-severe psoriasis: results from PHOENIX 1. British Journal of Dermatology (2014) 170, pp398–407"],"76":["Egeberg A,Ottosen M, Gniadecki R et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.Br J Dermatol. 2018 Feb;178(2):509-519"],"77":["Egeberg A,Ottosen M, Gniadecki R et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.Br J Dermatol. 2018 Feb;178(2):509-519"]}